Asston Pharmaceuticals Ltd (APL)

Loading page…

Asston Pharmaceuticals Ltd (APL) · mywealthgrid

About

Asston Pharmaceuticals Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹83 Cr

P/E

21.4×

P/B

2.1×

Dividend yield

ROE

10%

ROCE

12.3%

Debt / equity

0.13

OPM

-2.2%

EPS (TTM)

₹4.5

Book value

₹45.7

52-week high

—

52-week low

—

265 historical price candles were omitted because the exchange source has not been verified.

₹97.4-1.6%1Y

Quick read

rule-based

Pros

No positive flags triggered.

Cons

−Low return on equity of 10% (3-yr avg)

Research score

Structured signal from quality, growth, valuation and momentum.

57/100

Business quality: 38
Valuation: 76

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore

₹ Cr	Mar 2026
Revenue	25
COGS	17
Gross profit	8
	9
	-1
OPM %	-2.2%
Depreciation	0
Interest	1
	6
Profit before tax	5
Tax	1
Tax %	15.9%
PAT	4
PAT margin %	15.2%
EPS (₹)	4.9
EPS adjusted (₹)	4.6

₹ Cr	Mar 2026
Equity capital	9
Reserves	30
	5
	8
Total equity & liabilities	52
	11
CWIP	—
Investments	0
	41
Total assets	52

₹ Cr	Mar 2026
	-10
	-10
	21
Net cash flow	1
Free cash flow	-20
CFO / Operating profit %	—

Return on equity

7 years: —
5 years: —
3 years: —
Last year: 10%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2026
Margins
Gross margin %	31.6%
EBITDA margin %	-2.2%
EBIT margin %	-3.5%
PAT margin %	15.2%
Working capital
Receivable days	524
Inventory days	16
Payable days	121
NWC days	419
Leverage
Current ratio	4.51
Debt to EBITDA	—
Debt to equity	0.13
Interest coverage	8.3
Asset turnover	0.49
Return ratios
Return on assets %	7.5%
Return on capital employed %	12.3%
Return on equity %	10%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Jun 2025	Sep 2025	Mar 2026
	50.66%	50.66%	50.66%
	9.7%	6.04%	1.91%
	4.08%	0%	0%
Government	0%	0%	0%
	35.56%	43.3%	47.43%
No. of shareholders	662	751	687

Promoter holding up 0 percentage points since Jun 2025.

8 deals · 20 Aug 2026 – 1 Sept 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
1 Sept 2026	PRAKRUTI R PALI	Bulk	BSE	Buy	51,000	₹123.04	₹0.63 Cr
31 Aug 2026	PRAKRUTI R PALI	Bulk	BSE	Buy	1,00,000	₹123.88	₹1.24 Cr
31 Aug 2026	SNEHLATA MANOJ KATHOTIA	Bulk	BSE	Buy	43,000	₹119.10	₹0.51 Cr
28 Aug 2026	PRAKRUTI R PALI	Bulk	BSE	Buy	1,64,000	₹112.81	₹1.85 Cr
27 Aug 2026	PRAKRUTI R PALI	Bulk	BSE	Buy	2,40,000	₹103.69	₹2.49 Cr
26 Aug 2026	PRAKRUTI R PALI	Bulk	BSE	Buy	1,38,000	₹95.59	₹1.32 Cr
20 Aug 2026	VANITA ANILKUMAR KUMBHARE	Bulk	BSE	Sell	70,000	₹81.04	₹0.57 Cr
20 Aug 2026	SNEHLATA MANOJ KATHOTIA	Bulk	BSE	Buy	67,000	₹81.68	₹0.55 Cr

1–8 of 8

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Ashish Narayan SakalkarManaging Director
Saili Jayaram MoreWhole time Director and Chief Executive Officer
Sachin Chandrakant BadakhNon-Executive Director
Rishabh Kumar JainNon Executive Independent Director
Vijaya E ShahpurkarNon Executive Independent Director
Yogesh SupekarNon - Executive Non -Independent Director
Sandip SharmaNon- Executive Independent Director
Yashvardhan TupeNon- Executive Director
Sumit PawarChief Financial Officer
Rishi UpadhayaCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Asston Pharmaceuticals Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Annual Report FY2025from bse Summary

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

No events on record

Corporate actions, results dates and filings will appear here once ingested.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

20 announcementsExport CSV

5 Sept 2026, 1:09 pmOthers

Board Meeting Outcome for Allotment Of 24,10,431 Equity Shares Via Preferential Allotment

Outcome without intimation PDF

4 Sept 2026, 7:44 pmCorp. Action

Fixing Record Date

Record Date PDF

4 Sept 2026, 7:39 pmAGM/EGM

Fixing 29Th September 2026 As The Date For Convening The 7Th Annual General Meeting Of The Company.

AGM PDF

4 Sept 2026, 7:36 pmCompany Update

Announcement under Regulation 30 (LODR)-Meeting Updates

Meeting Updates PDF

4 Sept 2026, 7:35 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

4 Sept 2026, 7:33 pmCompany Update

Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s

Appointment of Statutory Auditor/s PDF

4 Sept 2026, 7:31 pmBoard Meeting

Board Meeting Outcome for Out Come Of The Board Meeting

Outcome of Board Meeting PDF

4 Sept 2026, 11:15 amInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

Date	Category	Subject	Filing
5 Sept 2026, 1:09 pm	Others Outcome without intimation	Board Meeting Outcome for Allotment Of 24,10,431 Equity Shares Via Preferential Allotment	PDF
4 Sept 2026, 7:44 pm	Corp. Action Record Date	Fixing Record Date	PDF

Loading announcements…

Ratio	Mar 2026
Margins
Gross margin %	31.6%
EBITDA margin %	-2.2%
EBIT margin %	-3.5%
PAT margin %	15.2%
Working capital
Receivable days	524
Inventory days	16
Payable days	121
NWC days	419
Leverage
Current ratio	4.51
Debt to EBITDA	—
Debt to equity	0.13
Interest coverage	8.3
Asset turnover	0.49
Return ratios
Return on assets %	7.5%
Return on capital employed %	12.3%
Return on equity %	10%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Asston Pharmaceuticals Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

No events on record

Announcements

Ratio timeline

Not in the F&O segment

No fund holdings on record

Quarterly record

Bulk & block deals

Board and management

No events on record

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Return on equity